SLC5A2 and cardiovascular disorder: As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Association’s Standards of Medical Care in Diabetes (248, 249).